Certain of Recipharm’s larger institutional shareholders, Första AP-fonden, Lannebo Fonder and Fjärde AP-fonden, support the cash offer for Consort Medical and have undertaken to fully support and vote in favour of a rights issue at a forthcoming general meeting of Recipharm and have also undertaken to subscribe for an amount corresponding to at least their respective pro rata share in a rights issue of SEK 2,000 million.
Certain of Recipharm’s larger institutional shareholders, Första AP-fonden, Lannebo Fonder and Fjärde AP-fonden (holding 7.4%, 7.1% and 5.1% of the total number of shares in Recipharm, respectively, and together 19.6%), support the cash offer for Consort Medical and have undertaken to fully support and vote in favour of a rights issue at a forthcoming general meeting of Recipharm and have also undertaken to subscribe for an amount corresponding to at least their respective pro rata share in a rights issue of SEK 2,000 million.
As previously announced, Recipharm’s largest shareholders, Thomas Eldered and Lars Backsell (who together hold 27.1% of the total number of shares in Recipharm), have already undertaken to vote in favour of the rights issue at the forthcoming general meeting of Recipharm and have also undertaken to subscribe for an amount corresponding to their respective pro rata share in a rights issue of SEK 2,000 million.
Thus, current shareholders in Recipharm, together holding 46.6% of the total number of shares and 82.3% of the votes in Recipharm, have undertaken to vote in favour of a rights issue at a forthcoming general meeting of Recipharm and have also undertaken to subscribe for their respective pro rata share in the rights issue.
For more information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, telephone: +46 8 602 52 10
Tobias Hägglöv, CFO, telephone: +46 8 602 45 00
This information is information that Recipharm AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above at 07:45 CET on 26 November, 2019.
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 7,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 7.2 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com.
IMPORTANT INFORMATION
This publication is neither an offer to buy or sell nor an invitation to tender or offer to buy or sell shares.
This press release is not being published in or distributed to or into and must not be mailed or otherwise distributed or sent in or into any country in which the distribution or offering would require any such additional measures to be taken or would be in conflict with any law or regulation in such country. Persons who receive this press release (including, without limitation, nominees, trustees and custodians) and are subject to the law of any such jurisdiction will need to inform themselves about, and observe, any applicable restrictions or requirements. Any failure to do so may constitute a violation of the securities laws of any such jurisdiction.
To the extent this press release contains forward-looking statements, such statements do not represent facts and are characterized by the words “will”, “expect”, “believe”, “estimate”, “intend”, “aim”, “assume” or similar expressions. Such statements express the intentions, opinions or current expectations and assumptions of Recipharm. Such forward-looking statements are based on current plans, estimates and forecasts which Recipharm has made to the best of its knowledge, but which do not claim to be correct in the future. Forward-looking statements are subject to risks and uncertainties that are difficult to predict and usually cannot be influenced by Recipharm. It should be kept in mind that the actual events or consequences may differ materially from those contained in or expressed by such forward-looking statements.
Publication on a website
A copy of this announcement will be made available, subject to certain restrictions relating to persons resident in restricted jurisdictions, on Recipharm’s website at www.recipharm.com/investor-
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com
